KaB-103

About Kanpecia

Kanpecia is a pre-clinical stage biotech company targeting the significant and underserved markets of chemotherapy-induced and androgenic alopecia with its topical candidate, KaB-103. The compound has demonstrated promising early efficacy in rodent models, outperforming minoxidil, and shows a favorable initial safety profile. Founded in 2021 and led by a team with strong academic, clinical, and business credentials, the company is positioned to advance its asset through development, though it faces the typical high risks of drug development and a competitive landscape.

About Kanpecia

Kanpecia is a pre-clinical stage biotech company targeting the significant and underserved markets of chemotherapy-induced and androgenic alopecia with its topical candidate, KaB-103. The compound has demonstrated promising early efficacy in rodent models, outperforming minoxidil, and shows a favorable initial safety profile. Founded in 2021 and led by a team with strong academic, clinical, and business credentials, the company is positioned to advance its asset through development, though it faces the typical high risks of drug development and a competitive landscape.

Therapeutic Areas